Michal Nath Puri
CIK: 0001997032
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NovoCure Ltd
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Jun 30, 2026NVCR
NovoCure Ltd
Award(A)Direct1.9K shares at avg. $11.15$21K - Mar 4, 2026NVCR
NovoCure Ltd
Sale(S)Direct1.1K shares at avg. $13.31$15K - Mar 3, 2026NVCR
NovoCure Ltd
Award(A)Direct40.1K shares- - Feb 27, 2026NVCR
NovoCure Ltd
Sale(S)Direct1.4K shares at avg. $13.66$20K - Dec 31, 2025NVCR
NovoCure Ltd
Award(A)Direct1 shares at avg. $10.99$10.99 - Oct 31, 2025NVCR
NovoCure Ltd
Tax Payment(F)Direct752 shares at avg. $12.82$10K - Jun 30, 2025NVCR
NovoCure Ltd
Award(A)Direct833 shares at avg. $15.13$13K - Mar 4, 2025NVCR
NovoCure Ltd
Award(A)Direct55K shares at avg. $18.19$1000K - Feb 27, 2025NVCR
NovoCure Ltd
Sale(S)Direct1.2K shares at avg. $19.92$23K - Feb 27, 2025NVCR
NovoCure Ltd
Sale(S)Direct225 shares at avg. $20.55$5K - Oct 31, 2024NVCR
NovoCure Ltd
Sale(S)Direct810 shares at avg. $15.79$13K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 30, 2026 | NVCR NovoCure Ltd | Award(A) | 1,905 | $11.15 | $21,241 | Direct |
| Mar 4, 2026 | NVCR NovoCure Ltd | Sale(S) | 1,100 | $13.31 | $14,636 | Direct |
| Mar 3, 2026 | NVCR NovoCure Ltd | Award(A) | 40,100 | - | $0 | Direct |
| Feb 27, 2026 | NVCR NovoCure Ltd | Sale(S) | 1,441 | $13.66 | $19,690 | Direct |
| Dec 31, 2025 | NVCR NovoCure Ltd | Award(A) | 1 | $10.99 | $11 | Direct |
| Oct 31, 2025 | NVCR NovoCure Ltd | Tax Payment(F) | 752 | $12.82 | $9,641 | Direct |
| Jun 30, 2025 | NVCR NovoCure Ltd | Award(A) | 833 | $15.13 | $12,603 | Direct |
| Mar 4, 2025 | NVCR NovoCure Ltd | Award(A) | 54,975 | $18.19 | $999,995 | Direct |
| Feb 27, 2025 | NVCR NovoCure Ltd | Sale(S) | 1,162 | $19.92 | $23,149 | Direct |
| Feb 27, 2025 | NVCR NovoCure Ltd | Sale(S) | 225 | $20.55 | $4,624 | Direct |
| Oct 31, 2024 | NVCR NovoCure Ltd | Sale(S) | 810 | $15.79 | $12,792 | Direct |
1-11 of 11 transactions
About Puri Michal Nath
Puri Michal Nath (SEC CIK 0001997032) files insider reports with the SEC as Chief Human Resources Officer of NovoCure Ltd (NVCR).
Signal8 holds 10 ownership filings by Puri Michal Nath (9 Form 4, 1 Form 5), filed between Nov 4, 2024 and Jul 1, 2026. Those filings report 11 transactions, from Oct 31, 2024 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Puri Michal Nath's filings is in WAYNE, PA.
Recent filings by Puri Michal Nath
- Jun 30, 2026: Grant or award of NVCR shares (Form 4, code A).
- Mar 4, 2026: Open-market sale of NVCR shares (Form 4, code S).
- Mar 3, 2026: Grant or award of NVCR shares (Form 4, code A).
- Feb 27, 2026: Open-market sale of NVCR shares (Form 4, code S).
- Dec 31, 2025: Grant or award of NVCR shares (Form 5, code A).
Other insiders filing for NovoCure Ltd (NVCR)
- Leonard Frank X, Chief Executive Officer
- Ben Arye Barak, General Counsel
- Danziger Asaf, Director
- LEUNG GABRIEL, Director
- Stafford Kristin, Director
- Ocean Allyson J, Director